Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-18 (bloomberglaw.com)
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent multiple sclerosis drug scheme, a federal appeals court said Friday.
Read more
2024-10-10 (marketbeat.com)
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays.
Read more
2024-07-05 (pr-inside.com)
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact ...
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact ...
Read more
2024-06-25 (canadianinsider.com)
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
The only place for free North American stock rankings incorporating insider commitment. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Home of the Canadian Insider Club which offers alerts and premium research.
Read more
2024-06-14 (wrbl.com)
BFA Law Notice: Biogen Inc. (Nasdaq: BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https:
Read more
2024-05-25 (globenewswire.com)
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects ...
Read more
2023-04-13 (biopharma-reporter.com)
Biogen opts into Alzheimer’s drug candidate from pact with Denali Therapeutics
As part of a $1 billion deal forged in 2020, Biogen has exercised the option to license a treatment candidate for Alzheimer’s disease developed by the US biotech company Denali Therapeutics.
Read more
2023-04-04 (masslawyersweekly.com)
Securities - Fraud - Knowingly
Where a securities fraud complaint has been filed over the failed commercial rollout of an innovative treatment for Alzheimer's disease, the complaint must be dismissed because (1) none of the defendants' 25 allegedly false and misleading statements are actionable under the Private Securities
Read more
2022-11-14 (rttnews.com)
Uptrend Continues For Biogen Shares
Shares of Biogen Inc. (BIIB) are gaining more than 5 percent on Monday morning trade continuing an uptrend since November 11. There were no corporate announcements on the day to influence the stock movement.
Read more
2022-03-04 (prnewswire.com)
Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022
/PRNewswire/ -- Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities of Biogen, Inc. ("Biogen" or...
Read more
2022-02-03 (pharmaphorum.com)
Biogen's former R&D chief Al Sandrock resurfaces at Voyager
Al Sandrock 's shock departure from Biogen in November sparked speculation about where he would show up next, and the answer came in today– gene therapy specialist Voyager Therapeutics.He has been appointed to Voyager Therapeutics' board as well as a new executive committee alongside interim CEO
Read more
2020-11-30 (biospace.com)
Biogen Bets $1.5 Billion on Sage Therapeutics' Drug for Depressive Disorders | BioSpace
Sage and Biogen forged the deal to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
Read more